This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor T cells. Join us Tuesday, May 26, 2020 at 8 PM EST.
Date/Time: Tuesday, May 26, 2020 at 8 PM EST
This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T cells. We will feature a panel of leading experts to discuss important topics and considerations surrounding CAR T-cell therapies and the patient populations impacted during this time.
Click here to register today!
Topics:
Faculty:
Loretta J. Nastoupil, MD, Associate Professor; Section Chief, Indolent Lymphoma; Section Chef, New Drug Development, Department Lymphoma/Myeloma, UT MD Anderson Cancer Center
Ahmed Galal, MD, FRACP, MSc, Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Duke School of Medicine
Matthew Lunning, DO, Associate Professor, Internal Medicine; Medical Director, Lymphoma Research, Division of Oncology & Hematology, University of Nebraska Medical Center
Sponsored By:
Keys to a Successful Cell and Gene Therapy Launch
February 16th 2025The success of cell and gene therapies relies not just on approvability but on affordability and accessibility. Innovative manufacturing, automation, and digital tools are key to expanding patient access and ensuring commercial viability.